Open Access
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
Francesco Massari,Chiara Ciccarese,Matteo Santoni,Antonio Lopez-Beltran,Marina Scarpelli,Rodolfo Montironi,Liang Cheng +6 more
TLDR
In this article, the role of FGF/FGFR pathway in renal cell carcinoma and ongoing trials of emerging agents targeting this axis is discussed, which is a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors.Abstract:
Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.read more
Citations
More filters
Journal ArticleDOI
FGF Family: From Drug Development to Clinical Application.
TL;DR: The applications of recombinant FGFs for the treatment of wounds, diabetes, hypophosphatemia, the development of FGF receptor inhibitors as anti-neoplastic drugs, and the achievements of basic research and applications of F GFs in China are reviewed.
Journal ArticleDOI
Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer.
Sherry Bhalla,Kumardeep Chaudhary,Ritesh Kumar,Manika Sehgal,Harpreet Kaur,Suresh Kumar Sharma,Gajendra P. S. Raghava +6 more
TL;DR: An attempt has been made to identify expression-based gene biomarkers that can discriminate early and late stage of clear cell renal cell carcinoma (ccRCC) patients and implied a need to develop gender-specific models for stage classification.
Journal ArticleDOI
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
TL;DR: The efficacy and safety results from the pivotal trials of these newly approved therapies, including the quality of study design, the level of evidence, subgroup analyses, and how these data can help to guide clinicians to select the most appropriate second-line therapy for their patients are discussed.
Journal ArticleDOI
The prospect of precision therapy for renal cell carcinoma.
Chiara Ciccarese,Matteo Brunelli,Rodolfo Montironi,Michelangelo Fiorentino,Roberto Iacovelli,Daniel Heng,Giampaolo Tortora,Francesco Massari +7 more
TL;DR: In this complex scenario, it is important to find prognostic and predictive factors that can help in decision making in the treatment of mRCC.
Journal ArticleDOI
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale
Viktor Grünwald,Thomas Powles,Toni K. Choueiri,Thomas E. Hutson,Camillo Porta,Masatoshi Eto,Cora N. Sternberg,Sun Young Rha,Cixin S He,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Robert J. Motzer +13 more
TL;DR: The rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvarinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC, are described.
References
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers,Douglas Hanahan +1 more
TL;DR: Emerging data support a proposition that two modes of unconventional resistance underlieAngiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
Journal ArticleDOI
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
TL;DR: Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis, finding phenotypic resistance to V EGFR2 blockade emerged.
Journal ArticleDOI
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.
TL;DR: This review will focus on the relevance of the FGF/FGF receptor system in adult angiogenesis and its contribution to tumor vascularization.
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Related Papers (5)
Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
Thomas Harding,Li Long,Servando Palencia,Hongbing Zhang,Ali Sadra,Kevin Hestir,Namrata Patil,Anita Levin,Amy W. Hsu,Deborah H. Charych,Thomas Brennan,James Zanghi,Robert Halenbeck,Shannon Marshall,Minmin Qin,Stephen Doberstein,Diane Hollenbaugh,W. Michael Kavanaugh,Lewis T. Williams,Kevin P. Baker +19 more